Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie

Needham & Company LLC Raises Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target to $18.00 - Defense World

Defense World

Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $18.00 at Mizuho - Defense World

Defense World

Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 3.8% - MarketBeat

MarketBeat

Plaque Psoriasis Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical ... - openPR

openPR

Plaque Psoriasis Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical ... - openPR

openPR

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Short Interest Update - MarketBeat

MarketBeat

When (ARQT) Moves Investors should Listen - Stock Traders Daily

Stock Traders Daily

Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Up After Better-Than-Expected Earnings - Defense World

Defense World

Arcutis Biotherapeutics (NASDAQ:ARQT) Posts Earnings Results - MarketBeat

MarketBeat

Arcutis shares surge on robust Zoryve franchise sales; stock PT raised by Needham - Investing.com South Africa

Investing.com South Africa

Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Up After Analyst Upgrade - MarketBeat

MarketBeat

Needham & Company LLC Boosts Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target to $18.00 - MarketBeat

MarketBeat

Arcutis shares surge on robust Zoryve franchise sales; stock PT raised by Needham - Investing.com

Investing.com

Arcutis Biotherapeutics surges 22% on Q1 beats (NASDAQ:ARQT) - Seeking Alpha

Seeking Alpha

Earnings call: Arcutis Biotherapeutics reports strong Q1 2024 growth - Investing.com

Investing.com

Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket - MSN

MSN

Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket - MSN

MSN

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket - Arcut - Benzinga

Benzinga

Mizuho lifts Arcutis shares target on strong quarter - Investing.com

Investing.com

Mizuho lifts Arcutis shares target on strong quarter - Investing.com UK

Investing.com UK

ARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q1 2024 - MSN

MSN

Arcutis Biotherapeutics Stock Climbs After Blockbuster Q1 Results - Arcutis Biotherapeutics (NASDAQ:ARQT) - Benzinga

Benzinga

Arcutis Biotherapeutics announces the JCAD published outcomes of ZORYVE - TipRanks.com - TipRanks

TipRanks

Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire Inc.

Arcutis Biotherapeutics options imply 12.9% move in share price post-earnings - TipRanks.com - TipRanks

TipRanks

Expert Panel Confirms Efficacy and Safety of Roflumilast Topical Foam for Seborrheic Dermatitis Across Diverse Hair ... - Dermatology Times

Dermatology Times

Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 5.4% - Defense World

Defense World

Arcutis Biotherapeutics (ARQT) to Release Quarterly Earnings on Tuesday - Defense World

Defense World

Los Angeles Capital Management LLC Acquires Shares of 194,461 Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat

MarketBeat

Los Angeles Capital Management LLC Acquires Shares of 194,461 Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat

MarketBeat

Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 5.4% - MarketBeat

MarketBeat

Arcutis Biotherapeutics (ARQT) Set to Announce Earnings on Tuesday - MarketBeat

MarketBeat

Seborrhoeic Dermatitis Market 2032: Epidemiology Review, Pipeline Breakthroughs, Regulatory Highlights by ... - openPR

openPR

Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Down 6.7% - Defense World

Defense World

Arcutis Biotherapeutics exec sells over $40k in company stock - Investing.com Australia

Investing.com Australia

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Down 6.7% - MarketBeat

MarketBeat

Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 8.9% - MarketBeat

MarketBeat

Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

GlobeNewswire Inc.

Industry Analysts Just Made A Captivating Upgrade To Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue ... - Yahoo Finance

Yahoo Finance

New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Simply Wall St

Simply Wall St

Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research

Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance UK

Yahoo Finance UK

Evaluating Arcutis Biotherapeutics: Insights From 5 Financial Analysts

Benzinga

Arcutis Biotherapeutics Welcomes New CFO David Topper - TipRanks.com - TipRanks

TipRanks

Arcutis Appoints David Topper as Chief Financial Officer

GlobeNewswire Inc.

Arcutis Appoints David Topper as Chief Financial Officer - Yahoo Finance Australia

Yahoo Finance Australia

Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?

Zacks Investment Research

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.